Asset Type: Webinars, Imaging, Imaging Core Lab, Oncology

Designing Multiple Myeloma Trials for More Accurate Endpoint Assessment

Designing Multiple Myeloma Trials for More Accurate Endpoint Assessment

Wednesday, Dec. 9 | 11:00 am ET

How can sponsors build endpoint accuracy into a multiple myeloma trial from the start? In this webinar, industry and academic experts will discuss key study design decisions, the logistical complexities that must be anticipated during trial execution, and the evolving role of minimal residual disease (MRD) in routine endpoint assessment ahead of upcoming guideline changes.

Join this engaging session and learn how to harmonize an approach for overcoming the common challenges in myeloma clinical trials, including evaluating local and central lab datasets for efficacy with emphasis on the confirmation of progression.


Register for the webinar

 
 

Meet Our Presenters

Amit Agarwal

Amit Agarwal, M.D., Ph.D.

Chief Medical Officer, BeOne Medicines

Dr. Agarwal is a board-certified hematologist and oncologist whose career began at the Univ. of Arizona cancer center where he focused on clinical and translational research, leading to the advancement of several therapies for hematological malignancies. Before joining BeOne, Amit held leadership positions at Arch Oncology and BMS/Celgene, where he contributed to the development of notable therapies such as Revlimid, Pomalyst, CelMods, bispecifics, CAR-T therapies, and immuno-oncology agents.

Shaji Kumar

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic 

Dr. Kumar is the Mark and Judy Mullins Professor of Hematological Malignancies, Chair, Myeloma, Amyloidosis and Dysproteinemia Disease Group, and Research Chair, Division of Hematology. His research centers on developing new drugs and drug combinations for treating myeloma and the mechanisms behind disease progression from precursor conditions and risk stratification of plasma cell disorders. He is the NCCN Multiple Myeloma Guidelines Panel Chair and Editor in Chief of The Hematologist.

Nikhil Munshi

Nikhil C. Munshi, MD

Chair and Professor of Medicine, Harvard Medical School

Dr. Munshi is Professor of Medicine at Harvard Medical School, Kraft Family Chair, and Associate Director of the Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute. His research spans myeloma genomics, genomic instability, and development of novel targeted and immune-based therapies. He has authored over 700 publications, mentored over 70 researchers, and served as President of the IMS. Honors include the Waldenström Lifetime Achievement Award and Dr. B.C. Roy National Award.

Zsolt Somodi

Zsolt Somodi, MD, MSc

Sr. Medical Director, Perceptive Imaging

Zsolt Somodi is a Senior medical Director and Scientific Leader at Perceptive Imaging. He has more than 25 years of experience spanning clinical practice and global oncology drug development, including early- and late-phase oncology and hematology trials. He has led several multiple myeloma trials at Perceptive and supported the development and harmonization of response evaluation within the central review framework.

Rusdia Yusuf

Rushdia Yusuf MD, MPH

Consultant, Perceptive Imaging (Moderator)

Dr. Yusuf completed her internal medicine residency and hematology-oncology fellowship at Mass. General Hospital and Dana-Farber Cancer Institute, where she later became an attending physician in bone marrow transplant and hematologic malignancies. She continued to see patients while holding progressive roles within both biotech and Big Pharma, conducting early and late phase clinical development in hematology and solid tumor indications − most recently as Lead of the Lymphoma Program at Merck.